Sunmed Capital

The firm's mandate covers healthcare services, digital health, and AI-enabled medical technologies. Public records suggest Sunmed is particularly interested in companies that integrate with China's public hospital infrastructure for diagnostic, therapeutic, or operational workflow applications. Its focus excludes therapeutics and biotech, where regulatory timelines and capital requirements diverge from its seed-stage model.

Sunmed's sourcing model relies on proximity to Shanghai's major academic medical centers, including the city's tier-one public hospitals. These institutions serve dual functions for portfolio companies — as clinical pilot sites and as reference customers. This hospital-anchored origination differentiates the firm from generalist Chinese VCs that source primarily through founder networks or demo days.

Sunmed's limited partner base has not been publicly disclosed. Shanghai-based venture firms of comparable size often raise capital from a mix of domestic high-net-worth individuals, family offices, and occasionally local government guidance funds. No specific institutional LPs or founding-family wealth origins have been publicly identified for Sunmed Capital.